Is SS-31 Better Than Elamipretide? (Comparison)

SS-31 and elamipretide aren't competing compounds. They're the same molecule. The confusion stems from naming conventions used at different stages of clinical development. The peptide now known as elamipretide was originally designated SS-31 during early preclinical research at Cornell University, where Hazel Szeto and Peter Schiller first synthesised the tetrapeptide sequence in the early 2000s. As the compound progressed through IND filing and Phase 2 trials, it received the International Nonproprietary Name (INN) elamipretide from the World Health Organization. The standardised naming system used globally for pharmaceutical substances.

Our team works directly with researchers evaluating mitochondrial-targeting compounds across cardiovascular, neurodegenerative, and metabolic disease models. The nomenclature distinction between SS-31 and elamipretide matters only for literature searches. Mechanistically, pharmacologically, and structurally, they're identical. This article covers the tetrapeptide's mechanism of action, the clinical evidence base under both names, and how researchers should navigate the dual nomenclature when sourcing materials or citing studies.

Is SS-31 better than elamipretide?

SS-31 is not better or worse than elamipretide because they are the same tetrapeptide: D-Arg-Dmt-Lys-Phe-NH2. SS-31 is the laboratory designation used during early-stage research; elamipretide is the INN assigned when the compound entered formal clinical development. Both names refer to the mitochondrial-targeting peptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilising cristae structure and reducing reactive oxygen species (ROS) production.

The question 'is SS-31 better than elamipretide' arises from researchers encountering both names in published literature without realising they describe the same compound. Early preclinical papers (2005–2012) predominantly use SS-31; Phase 2 and Phase 3 trial reports use elamipretide. The peptide's mechanism. Cardiolipin binding leading to improved electron transport chain efficiency and reduced oxidative damage. Remains unchanged across nomenclature. Understanding this equivalence prevents researchers from mistakenly treating them as competing compounds when designing studies or sourcing peptides for laboratory work.

The Molecule Behind Both Names: Structure and Mechanism

SS-31 (elamipretide) is a four-amino-acid peptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt represents 2',6'-dimethyltyrosine. A non-standard aromatic amino acid that confers lipophilicity and structural rigidity. The D-arginine at position 1 provides a cationic charge that drives mitochondrial uptake, while the aromatic Dmt and Phe residues enable hydrophobic insertion into membrane bilayers. This tetrapeptide selectively binds cardiolipin, a phospholipid unique to the inner mitochondrial membrane that anchors respiratory chain complexes and maintains cristae architecture.

Cardiolipin oxidation. Triggered by excessive ROS production during ischemia, heart failure, or neurodegenerative disease. Destabilises cristae structure, impairs Complex I and Complex IV activity, and increases mitochondrial membrane permeability. Elamipretide's binding to cardiolipin prevents this oxidative damage cascade by physically stabilising the lipid-protein interface and reducing electron leak from Complex I, the primary site of superoxide generation. The result is a 40–60% reduction in ROS production, improved ATP synthesis efficiency (measured as P/O ratio), and restoration of mitochondrial membrane potential. Outcomes demonstrated consistently across preclinical models from ischemia-reperfusion injury to Barth syndrome.

The peptide's pharmacokinetics are defined by rapid plasma clearance (half-life approximately 1.5 hours) and extensive tissue distribution driven by its mitochondrial-targeting cationic charge. Following intravenous administration, elamipretide accumulates in tissues with high mitochondrial density. Cardiac myocytes, skeletal muscle, renal tubular cells, and neurons. At concentrations 100–1000 times higher than plasma levels. This selective tissue uptake explains the compound's efficacy in organ-specific mitochondrial dysfunction without systemic toxicity. Researchers evaluating Real Peptides' mitochondrial support formulations benefit from this same precision in compound design.

Clinical Evidence: What Both Names Represent in Published Trials

The compound's progression from SS-31 (preclinial) to elamipretide (clinical) reflects advancing regulatory development stages, not changes in the molecule itself. Early foundational work published between 2006 and 2012 under the SS-31 designation established cardiolipin binding as the primary mechanism and demonstrated protective effects in rodent models of myocardial infarction, renal ischemia, and sepsis. These studies, conducted primarily at Cornell and published in journals including Circulation Research and the Journal of Molecular and Cellular Cardiology, showed 50–70% reductions in infarct size and preservation of mitochondrial respiratory capacity when SS-31 was administered before or immediately after ischemic insult.

Phase 1 and Phase 2 trials conducted under the elamipretide INN designation confirmed safety in humans and demonstrated measurable improvements in 6-minute walk distance in patients with mitochondrial myopathy. A rare genetic disorder characterised by impaired oxidative phosphorylation. The Phase 2 trial in Barth syndrome, published in Genetics in Medicine (2020), showed a mean 48-meter improvement in 6-minute walk distance versus placebo after 12 weeks of subcutaneous elamipretide at 40mg daily. These patients carry mutations in the TAZ gene (encoding tafazzin, the enzyme that remodels cardiolipin), making them uniquely dependent on cardiolipin stabilisation. The exact function elamipretide provides.

The compound did not meet primary endpoints in Phase 3 heart failure trials (PROGRESS-HF), where it failed to demonstrate statistically significant improvement in peak VO2 max or left ventricular end-diastolic volume at 28 weeks. This outcome reflects the challenge of treating chronic, multifactorial heart failure with a single mitochondrial intervention. Not a failure of the underlying cardiolipin-binding mechanism. Post-hoc analyses suggested potential benefit in subgroups with more severe mitochondrial dysfunction, but the sponsor (Stealth BioTherapeutics) has not pursued further cardiac indications. Current clinical focus remains on rare mitochondrial diseases where cardiolipin dysfunction is the primary pathology.

SS-31 vs Elamipretide: Side-by-Side Comparison

Because the question 'is SS-31 better than elamipretide' reflects nomenclature confusion rather than a genuine comparison of distinct compounds, this table clarifies what each name represents, when each is used, and how researchers should interpret literature using either designation.

The practical implication: researchers citing studies should use the name that appears in the original publication (SS-31 for early mechanism work, elamipretide for clinical trials), but recognise both refer to the same compound when interpreting cross-study findings. Quality researchers at institutions like Real Peptides maintain rigorous sequencing verification regardless of nomenclature.

Key Takeaways

• SS-31 and elamipretide are the same tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2). SS-31 is the early laboratory designation, elamipretide is the WHO-assigned INN used in clinical development.
• The compound works by selectively binding cardiolipin in the inner mitochondrial membrane, stabilising cristae structure and reducing ROS production by 40–60% in preclinical models.
• Early preclinical literature (2005–2012) uses SS-31; Phase 2 and Phase 3 human trials use elamipretide. Both names describe identical pharmacological activity.
• Phase 2 trials in Barth syndrome showed a 48-meter improvement in 6-minute walk distance, but Phase 3 heart failure trials (PROGRESS-HF) did not meet primary endpoints.
• When sourcing peptides for research, verify amino acid sequence and purity documentation. The name SS-31 or elamipretide alone doesn't guarantee compound quality or correct synthesis.

What If: SS-31/Elamipretide Scenarios

What If I Find Studies Using SS-31 and Others Using Elamipretide — Are They Studying Different Compounds?

No. They're studying the same molecule. Use both search terms when conducting literature reviews to capture the full evidence base. PubMed searches for 'SS-31' return primarily preclinical mechanistic studies, while 'elamipretide' returns clinical trial reports. Combining both terms ('SS-31 OR elamipretide') gives comprehensive coverage. The mechanism, structure, and pharmacology remain identical regardless of which name appears in the title.

What If I'm Designing a Study and Need to Source This Peptide — Which Name Should I Use When Ordering?

Request the peptide by its chemical sequence (D-Arg-Dmt-Lys-Phe-NH2) rather than relying solely on the trade name. Reputable synthesis vendors will provide mass spectrometry verification showing the exact molecular weight (640.78 g/mol) and HPLC purity data. Some suppliers list it as SS-31, others as elamipretide, others as Bendavia. The sequence is the definitive identifier. Researchers using Energy Mitochondria Fatigue Bundle formulations benefit from this same verification standard across all mitochondrial-targeting compounds.

What If I'm Citing This Peptide in a Grant Application — Which Name Is More Appropriate?

Use 'elamipretide (SS-31)' on first mention, then elamipretide alone throughout. This approach acknowledges the historical nomenclature while using the INN-standardised name that regulatory bodies and funding agencies recognise. If your work builds on early SS-31 mechanism papers, cite those papers using the name that appeared in the original publication. But clarify in your narrative that SS-31 and elamipretide refer to the same compound to avoid confusion among reviewers unfamiliar with the dual nomenclature.

The Unfiltered Truth About SS-31 vs Elamipretide

Here's the honest answer: asking whether SS-31 is better than elamipretide is like asking whether H2O is wetter than water. They're the same molecule, separated only by naming convention and development timeline. The confusion exists because researchers encounter both names in literature searches and assume they represent competing compounds. They don't. The cardiolipin-binding tetrapeptide synthesised at Cornell in 2005 under the laboratory code SS-31 is molecularly identical to the INN-designated elamipretide tested in Phase 3 trials in 2019. Every mechanism study, every pharmacokinetic profile, every clinical outcome applies to both names equally.

The real question isn't which name is better. It's whether this peptide's mitochondrial-targeting mechanism translates into meaningful therapeutic benefit for human disease. The answer is nuanced: yes for rare mitochondrial myopathies where cardiolipin dysfunction is the primary defect, unclear for complex multifactorial conditions like heart failure where mitochondrial dysfunction is one of many contributing pathologies. The Phase 3 heart failure trial failure doesn't invalidate the mechanism. It reveals the limits of single-target interventions in diseases with ten contributing factors. For researchers working in mitochondrial biology, both names represent the same valuable tool for probing cardiolipin's role in cristae integrity and oxidative phosphorylation efficiency.

Anyone claiming SS-31 works differently than elamipretide, or that one is a 'newer' or 'improved' version of the other, is either confused or deliberately misleading. The peptide sequence hasn't changed. The binding site hasn't changed. The only thing that changed was regulatory nomenclature as the compound advanced from lab bench to clinic. We mean this sincerely: verify the amino acid sequence, confirm purity documentation, and ignore the name games. The science is in the sequence, not the label.